Welcome to Pipeline Review

Generex Biotechnology, and their wholly owned subsidiary Antigen Express, are developing promising new drugs to treat diabetes, as well as synthetic peptide vaccines targeting HER2/neu cancer and pandemic flu. The flagship product for Generex is Oral-lyn buccal insulin. Antigen Express' leading vaccine is the AE37 HER2/neu synthetic peptide vaccine to prevent breast cancer recurrence. I am not qualified to offer investment or medical advice, and make no claims that I am an expert in these areas. I am a layman and a shareholder in this company. The left side of Pipeline Review holds blogs regarding Generex and Antigen Express, while the right side offers items of due diligence mixed with my analysis which may be of interest to others seeking to learn about Generex's pipeline. If the left side only shows the latest blog, click on the word home to view them all.

Search This Blog

Tuesday, March 27, 2012

Two Late Breaking Abstracts Featuring Antigen Express' AE37 Peptide Vaccine for HER2/Neu Breast Cancer Patients to be Presented at AACR 2012




The AACR Annual Meeting will highlight the best and latest findings in all major areas of cancer research. Cancer researchers continue to make incredible strides and breakthroughs, with an impact on global health. The theme of the AACR Annual Meeting 2012, “Accelerating Science: Concept to Clinic,” reflects this amazing progress and emphasizes the synergy between basic, clinical and translational research that will continue to lead to effective cancer therapies and prevention strategies. The meeting takes place March 31-April 4 in Chicago.

Two late breaking abstracts featuring Antigen Express' AE37 Peptide Vaccine for HER2/Neu breast cancer patients will be presented at the AACR Annual Meeting. The titles of the abstracts, and names of the authors, have been made available at the meetings website:

Late-Breaking Poster Session
LBPO.IM01. Late-Breaking Research: Immunology
Mon, Apr 2, 1:00 - 5:00 PM

Abstract Number:
LB-130

Presentation Title:
Immune reconstitution after chemotherapy correlates with increased in vitro immune response in breast cancer patients undergoing peptide vaccine therapy

Location:
McCormick Place West (Hall F), Poster Section 40

Author Block:
Timothy J. Vreeland, Raetasha S. Dabney, Diane F. Hale, Alan K. Sears, Guy T. Clifton, Athina Zacharia, Yusuf Jama, Anna Chiplis, Mohamed Mursal, Nathan M. Shumway, Ritesh Patil, Jarrod P. Holmes, Elizabeth A. Mittendorf, George E. Peoples, Sathibalan Ponniah. San Antonio Military Medical Center, San Antonio, TX, Cancer Vaccine Development Lab, USUHS, Bathesda, MD, Roswell Park Cancer Institute, Buffalo, NY, Redwood Regional Medical Group, Santa Rosa, CA, UTMD Anderson, Houston, TX


Late-Breaking Poster Session
LBPO.CL01. Late-Breaking Research: Clinical Trials
Tue, Apr 3, 8:00 AM - 12:00 PM

Abstract Number:
LB-218

Presentation Title:
Immune response assessment in a phase II trial of AE37 HER2 peptide vaccine

Location:
McCormick Place West (Hall F), Poster Section 40

Author Block:
Diane F. Hale, Timothy J. Vreeland, Raetasha S. Dabney, G Travis Clifton, Alan K. Sears, Efi Pappou, Eleftheria Anastasopoulou, Alexandros Ardavanis, Sathibalan Ponniah, Michael Papamichail, Sonia Perez, Nathan Shumway, George E. Peoples, Elizabeth Mittendorf. Brooke Army Medical Center, Ft. Sam Houston, TX, St. Savas Cancer Hospital, Athens, Greece, Athens, Greece, Cancer Vaccine Development Lab, U.S. Military Cancer Institute, Uniformed Services University of the Health Sciences, Bethesda, MD, University of Texas MD Anderson Cancer Center, Houston, TX



The AACR 2012 website can be found by clicking here.